Phlow and Antheia Partner to Onshore US Fermentation Drug Ingredients

Partnership aims to reduce supply risks by shifting key pharmaceutical inputs closer to home

16 Dec 2025

Phlow and Antheia have agreed to work together to produce selected pharmaceutical ingredients in the US, as drugmakers and policymakers seek to reduce reliance on overseas manufacturing for essential medicines.

The partnership will focus on fermentation-based ingredients used in products such as antibiotics, which are currently made largely outside the US. While offshore production has lowered costs over time, it has also exposed supply chains to shipping delays, factory disruptions and geopolitical risks. Recent drug shortages have brought those vulnerabilities into sharper focus.

Under the agreement, the companies plan to use modern biosynthesis and continuous flow chemistry rather than traditional large-scale fermentation plants abroad. The aim is to produce more predictable and resilient supplies of critical inputs, subject to regulatory approvals.

Phlow specialises in manufacturing finished medicines and works closely with US government health agencies to secure dependable supplies of essential drugs. Antheia develops biological production platforms designed to deliver consistent pharmaceutical ingredients at commercial scale. The companies said combining these capabilities would allow new manufacturing models to be tested domestically.

Industry analysts view the move as part of a cautious shift rather than a wholesale reshoring of pharmaceutical production. Instead of reversing decades of globalisation, companies are selectively exploring technologies that may balance efficiency with greater resilience.

Proponents argue that domestic production could offer longer-term benefits. These include shorter development timelines, lower waste and faster responses to changes in demand, including during public health emergencies. More flexible manufacturing, they say, could help reduce the shortages that have affected hospitals in recent years.

Challenges remain significant. Advanced manufacturing facilities require substantial upfront investment, and new production methods must meet regulatory standards before being widely adopted. Cost competitiveness will depend on reliable demand and long-term purchasing commitments from buyers, including government agencies.

Even so, the collaboration carries symbolic importance. By treating fermentation as a strategic capability rather than a function to outsource, Phlow and Antheia are testing whether innovation and domestic manufacturing can advance together. The results may influence how future supplies of essential medicines are produced.